Health Editor’s Note: COVID-19 has been a blank slate for cures and treatments. We are looking at a novel or new coronavirus and before meeting COVID-19 the medical world had no idea how to conquer this virus which behaves differently than other coronaviruses. One of the traits, that causes so many deaths, is the fact that COVID-19 sends the body’s immune system into hyper-drive.
Remestemcel-L was designed to be used in children who have had bone marrow transplants to prevent rejection of the host cells. The inflammation that appears in COVID-19 is similar, so it is hoped that Remestemcel-L will aid in dealing with the hyper-inflammation process that can accompany acute respiratory distress syndrome which is a marker for COVID-19…..Carol
Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19
by Hannah Slater/Cancer Network
Mount Sinai Health System announced that they will be using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy, in patients with coronavirus disease 2019 (COVID-19).
Remestemcel-L has previously been tested in patients who have had a bone marrow transplant, who can experience an overactive immune response similar to that observed in severe cases of COVID-19.
Mount Sinai began administering remestemcel-L to patients in late March under the FDA’s compassionate use program. The therapy was given to 10 patients with moderate to severe cases of COVID-19-related acute respiratory distress syndrome (ARDS), most of whom were on ventilators, and the doctors saw encouraging results.
“We are encouraged by what we have seen so far and look forward to participating in the randomized controlled trial starting soon that would better indicate whether this is an effective therapy for patients in severe respiratory distress from COVID-19,” Keren Osman, MD, medical director of the Cellular Therapy Service in the Bone Marrow and Stem Cell Transplantation Program at …read more: